Rekah Pharmaceutical Industry Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Mordechai Elgrabli
Chief executive officer
₪857.0k
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 10.3yrs |
| CEO ownership | 15.3% |
| Management average tenure | no data |
| Board average tenure | 9.5yrs |
Recent management updates
Recent updates
Is Rekah Pharmaceutical Industry (TLV:REKA) A Risky Investment?
May 27
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up
Jul 11Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden
Jul 05Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year
Dec 14Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet
Sep 12Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Jul 19Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit
Apr 13We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt
May 12Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today
Apr 09Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?
Mar 12Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 19
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?
Jan 29Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock
Jan 08How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?
Dec 18Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | ₪3m |
| Dec 31 2024 | ₪857k | ₪857k | ₪6m |
| Sep 30 2024 | n/a | n/a | ₪8m |
| Jun 30 2024 | n/a | n/a | ₪7m |
| Mar 31 2024 | n/a | n/a | -₪6m |
| Dec 31 2023 | ₪1m | ₪1m | -₪7m |
| Sep 30 2023 | n/a | n/a | -₪8m |
| Jun 30 2023 | n/a | n/a | -₪3m |
| Mar 31 2023 | n/a | n/a | -₪2m |
| Dec 31 2022 | ₪845k | ₪845k | -₪2m |
| Sep 30 2022 | n/a | n/a | ₪4m |
| Jun 30 2022 | n/a | n/a | ₪3m |
| Mar 31 2022 | n/a | n/a | ₪5m |
| Dec 31 2021 | ₪830k | ₪830k | ₪7m |
| Sep 30 2021 | n/a | n/a | ₪5m |
| Jun 30 2021 | n/a | n/a | ₪9m |
| Mar 31 2021 | n/a | n/a | ₪10m |
| Dec 31 2020 | ₪828k | ₪828k | ₪11m |
| Sep 30 2020 | n/a | n/a | ₪7m |
| Jun 30 2020 | n/a | n/a | ₪5m |
| Mar 31 2020 | n/a | n/a | ₪4m |
| Dec 31 2019 | ₪832k | ₪832k | ₪3m |
| Sep 30 2019 | n/a | n/a | ₪6m |
| Jun 30 2019 | n/a | n/a | ₪5m |
| Mar 31 2019 | n/a | n/a | ₪7m |
| Dec 31 2018 | ₪801k | ₪801k | ₪8m |
Compensation vs Market: Mordechai's total compensation ($USD257.29K) is below average for companies of similar size in the IL market ($USD442.22K).
Compensation vs Earnings: Mordechai's compensation has been consistent with company performance over the past year.
CEO
Mordechai Elgrabli (81 yo)
Mr. Mordechai Elgrabli has been the Chief Executive Officer of Rekah Pharmaceutical Industry Ltd since August 24, 1993 and its Director since August 24, 1993. Mr. Elgrabli is a Member of Presidium of Mofet...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 31.9yrs | ₪857.00k | 15.32% ₪ 21.4m | |
| Director of Industrial Division & Director | 31.9yrs | ₪1.22m | 15.32% ₪ 21.4m | |
| Director | 10.3yrs | no data | no data | |
| Chairman | 10.3yrs | ₪250.00k | no data | |
| Independent External Director | 1.2yrs | no data | no data | |
| Independent External Director | 8.7yrs | no data | no data | |
| Independent External Director | 8.7yrs | no data | no data | |
| Director | 1.6yrs | no data | no data |
Experienced Board: REKA's board of directors are considered experienced (9.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/13 10:01 |
| End of Day Share Price | 2025/07/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rekah Pharmaceutical Industry Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.